Ipsen, an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed the results of a first phase III clinical study using Taspoglutide, the first human once weekly glucagon-like peptide-1 analogue originating from Ipsen's Research.
Roche discloses the results of first phase III clinical study using taspoglutide